No abstract

Peptide nucleic acids (PNA) are synthetic analog of DNA with a repeating N-(2-aminoethyl)-glycine peptide backbone connected to purine and pyrimidine nucleobases via a linker. Considering the unique properties of PNA, including resistance to enzymatic digestion, higher biostability combined with great hybridization affinity toward DNA and RNA, it has attracted great attention toward PNA- based technology as a promising approach for gene alteration. However, an important challenge in utilizing PNA is poor intracellular uptake. Therefore, some strategies have been developed to enhance the delivery of PNA in order to reach cognate site. Although PNAs primarily demonstrated to act as an antisense and antigene agents for inhibition of transcription and translation of target genes, more therapeutic applications such as splicing modulation and gene editing are also used to produce specific genome modifications. Hence, several approaches based on PNAs technology have been designed for these purposes. This review briefly presents the properties and characteristics of PNA as well as different gene modulation mechanisms. Thereafter, current status of successful therapeutic applications of PNA as gene therapeutic intervention in different research areas with special interest in medical application in particular, anti-cancer therapy are discussed. Then it focuses on possible use of PNA as anti-mir agent and PNA-based strategies against clinically important bacteria.

PTEN (Phosphatase and tensin homolog deleted on chromosome ten) is a tumor suppressor that is frequently mutated in most human cancers. PTEN is a lipid and protein phosphatase that antagonizes PI3K/AKT pathway through lipid phosphatase activity at the plasma membrane. More recent studies showed that, in addition to the putative role of PTEN as a PI(3,4,5)P3 3-phosphatase, it is a PI(3,4)P2 3-phosphatase during stimulation of class I PI3K signaling pathway by growth factor. Although PTEN tumor suppressor function via it's lipid phosphatase activity occurs primarily in the plasma membrane, it can also be found in the nucleus, in cytoplasmic organelles and extracellular space. PTEN has also shown phosphatase independent functions in the nucleus. PTEN can exit from the cell through exosomal export or secretion and has a tumor suppressor function in adjacent cells. PTEN has a critical role in growth, the cell cycle, protein synthesis, survival, DNA repair and migration. Understanding the regulation of PTEN function, activity, stability, localization and its dysregulation outcomes and also the intracellular and extracellular role of PTEN and paracrine role of PTEN-L in tumor cells as an exogenous therapeutic agent can help to improve clinical conceptualization and treatment of cancer.

Natural killer (NK) cells have significant capability in tumor immune-surveillance. The ability of lyse transformed cells immediately in an antigen-independent manner make them an attractive candidate for cancer cell therapy. Despite employment of NK cells in cancer immunotherapy, clinical trials are faced with serious limitations such as trouble with the penetration of NK cells in tumor sites, limited in vivo persistence, and tumor microenvironment interference. Taken together, the NK-cell cancer therapy is still infant scenario that has a long way to be translated in clinic. Current article first reviews characteristic features of NK lymphocytes. Then, it discusses about important disruptive barriers and motivator in the developmental stages of NK cells like as tumor microenvironment. Finally, some revolutionary approaches are highlighted utilizing of NK cells in cancer therapy.

Platelet (PLT) transfusions are potentially life saving for individuals with low PLT numbers; however, previous work revealed that PLT transfusions are associated with increased infection risk. During storage, PLT intended for transfusion continuously shed ectosomes (Ecto) from their surface, which express immunomodulatory molecules like phosphatidylserine or TGF-β1. Recently, PLT-Ecto were shown to reduce proinflammatory cytokine release by macrophages and to favor the differentiation of naive T cells toward regulatory T cells. Whether PLT-Ecto modify NK cells remains unclear. We exposed purified NK cells and full PBMCs from healthy donors to PLT-Ecto. We found a reduced expression of several activating surface receptors (NKG2D, NKp30, and DNAM-1) and decreased NK cell function, as measured by CD107a expression and IFN-γ production. Pretreatment of PLT-Ecto with anti–TGF-β1 neutralizing Ab restored surface receptor expression and NK cell function. We further observed a TGF-β1–mediated upregulation of miR-183, which, in turn, reduced DAP12, an important protein for stabilization and downstream signaling of several activating NK cell receptors. Again, these effects could antagonized, in part, when PLT-Ecto were preincubated with anti–TGF-β1 Ab. Erythrocyte Ecto did not affect NK cells. Polymorphonuclear cell Ecto expressed MHC class I and inhibited NK cell function. In addition, they induced the secretion of TGF-β1 by NK cells, which participated in an auto/paracrine manner in the suppressive activity of polymorphonuclear cell–derived Ecto. In sum, our study showed that PLT-Ecto could inhibit NK cell effector function in a TGF-β1–dependent manner, suggesting that recipients of PLT transfusions may experience reduced NK cell function.

No abstract

The earliest stages of natural killer (NK)-cell development are not well characterized. In this study, we investigated in different fetal hematopoietic tissues how NK-cell progenitors and their mature NK-cell progeny emerge and expand during fetal development. Here we demonstrate, for the first time, that the counterpart of adult BM Lin ؊ CD122 ؉ NK1.1 ؊ DX5 ؊ NK-cell progenitor (NKP) emerges in the fetal liver at E13.5. After NKP expansion, immature NK cells emerge at E14.5 in the liver and E15.5 in the spleen. Thymic NK cells arise at E15.5, whereas functionally competent cytotoxic NK cells were present in the liver and spleen at E16.5 and E17.5, respectively. Fetal NKPs failed to produce B and myeloid cells but sustained combined NK-and T-lineage potential at the single-cell level. NKPs were also found in the fetal blood, spleen, and thymus. These findings show the emergence and expansion of bipotent NK/T-cell progenitor during fetal and adult lymphopoiesis, further supporting that NK/T-lineage restriction is taking place prethymically. Uncovering the earliest NK-cell developmental stages will provide important clues, helping to understand the origin of diverse NK-cell subsets, their progenitors, and key regulators. In adult mice and man, the BM is the main site of NK-cell development 1,2 ; however, a distinct population of NK cells develops in the thymus. 3 These thymic-dependent NK cells play a regulatory function by producing a variety of cytokines and display poor cytotoxic activity compared to conventional BM NK cells. 3 The earliest progenitor committed to the NK-cell lineage (NKP) has been identified in adult mouse BM as having the Lin Ϫ CD122 ϩ NK1.1 Ϫ DX5 Ϫ phenotype. 4 However, we have recently shown that a sizable fraction of Lin Ϫ CD122 ϩ NK1.1 Ϫ DX5 Ϫ cells in adult mouse BM sustains the ability to also generate T cells, thus representing a bipotent NK/T-cell progenitor. 5 The generation of all blood cell lineages depends on a small population of HSCs. 6 The liver is the main site of hematopoiesis during mouse fetal development. 7 HSCs in the embryo originate within the intraembryonic sites: aorta-gonad-mesonephros region derived from the paraaortic splanchnopleura and placenta, as well as in the extra embryonic site in the yolk sac. [7][8][9][10] The fetal liver starts to be colonized by hematopoietic progenitors between E10 and E12, and from E12 to E15 the number of HSCs increases exponentially. 11,12 The thymic rudiment develops in the mouse fetus by E10, and its colonization starts between E11 and E12, whereas the spleen develops as a hematopoietic organ at E13 and hematopoietic progenitors are first detected around E15. 12,13 Hematopoietic progenitor cells appear in the femoral BM at E17, and after birth the BM becomes the main site for hematopoiesis while the hematopoietic activity in the liver and spleen declines. 11,12 Multiple fetal hematopoietic tissues, including the liver, thymus, and spleen, contain hematopoietic progenitors shown to have potential to generate NK cells. [14][15][16][...

Caspase-3 plays a vital role in intrinsic and extrinsic pathways of programed cell death and in cell proliferation. Its detection is an important tool for early detection of some cancers and apoptosis-related diseases, and for monitoring the efficacy of pharmaceuticals and of chemo- and radiotherapy of cancers. This review (with 72 references) summarizes nanomaterial based methods for signal amplification in optical methods for the determination of caspase-3 activity. Following an introduction into the field, a first large section covers optical assays, with subsections on luminescent and chemiluminescence, fluorometric (including FRET based), and colorimetric assays. Further section summarize methods for bioimaging of caspase-3. A concluding section covers current challenges and future perspectives. Graphical Abstract ᅟ.